STAC3 and prostate cancer: NAM is a noncompetitive inhibitor that blocks SIRTs deacetylation activity [45], disclosing anti-neoplastic effect in leukemia, oral squamous cell carcinoma, and prostate cancer by decreasing cell viability and proliferation, while inducing apoptosis [46,47].